To determine the potential involvement of these drug efflux pumps in the clinical setting, here we report results from a retrospective study of both MDR1/P-gp and MRP-1 protein expression and their associations with patients' clinicopathological features (where possible) in 134 melanomas, including 92 primary tumours and 42 metastases. This evidence concerns the gene PGP and melanoma.